Crescent Capital BDC (CCAP)
(Delayed Data from NSDQ)
$18.77 USD
-0.12 (-0.64%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $18.76 -0.01 (-0.05%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$18.77 USD
-0.12 (-0.64%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $18.76 -0.01 (-0.05%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth C Momentum C VGM
Zacks News
Crescent Capital BDC (CCAP) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
Crescent Capital BDC (CCAP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Best Momentum Stock to Buy for June 12th
by Zacks Equity Research
ASBFY, CCAP and CALM made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 12, 2024.
What Makes Crescent Capital BDC (CCAP) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Crescent Capital BDC (CCAP) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks Industry Outlook Highlights Golub Capital BDC and Crescent Capital BDC
by Zacks Equity Research
Golub Capital BDC and Crescent Capital BDC are part of the Zacks Industry Outlook article.
2 SBIC & Commercial Finance Stocks to Buy Despite Industry Woes
by Swayta Shah
Weak asset quality, high rates and macroeconomic woes are likely to hurt Zacks SBIC & Commercial Finance industry players like Golub Capital (GBDC) and Crescent Capital (CCAP). Yet, decent financing demand across sectors is likely to aid.
Has American Coastal Insurance Corporation (ACIC) Outpaced Other Finance Stocks This Year?
by Zacks Equity Research
Here is how American Coastal Insurance (ACIC) and Crescent Capital BDC (CCAP) have performed compared to their sector so far this year.
All You Need to Know About Crescent Capital BDC (CCAP) Rating Upgrade to Buy
by Zacks Equity Research
Crescent Capital BDC (CCAP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Crescent Capital BDC (CCAP) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Crescent Capital BDC (CCAP) delivered earnings and revenue surprises of 6.78% and 4.25%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Regency Centers (REG) Surpasses Q1 FFO Estimates
by Zacks Equity Research
Regency Centers (REG) delivered FFO and revenue surprises of 3.85% and 1.67%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Crescent Capital BDC (CCAP) Stock Moves -1.05%: What You Should Know
by Zacks Equity Research
Crescent Capital BDC (CCAP) closed at $17 in the latest trading session, marking a -1.05% move from the prior day.
Is It Worth Investing in Crescent Capital BDC (CCAP) Based on Wall Street's Bullish Views?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Crescent Capital BDC (CCAP) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Crescent Capital BDC (CCAP) Increases Yet Falls Behind Market: What Investors Need to Know
by Zacks Equity Research
Crescent Capital BDC (CCAP) closed at $17.50 in the latest trading session, marking a +0.81% move from the prior day.
Zacks Industry Outlook Highlights Bain Capital Specialty Finance, Barings BDC and Crescent Capital
by Zacks Equity Research
Bain Capital Specialty Finance, Barings BDC and Crescent Capital have been highlighted in this Industry Outlook article.
3 SBIC & Commercial Finance Stocks to Buy Amid Grim Industry Prospects
by Swayta Shah
Weak asset quality, high rates and macroeconomic woes are likely to hurt Zacks SBIC & Commercial Finance industry players like Bain Capital (BCSF), Barings BDC (BBDC) and Crescent Capital (CCAP). Yet, decent financing demand across sectors is likely to aid.
Here's Why Crescent Capital BDC (CCAP) Fell More Than Broader Market
by Zacks Equity Research
Crescent Capital BDC (CCAP) closed at $16.99 in the latest trading session, marking a -1.51% move from the prior day.
Is Crescent Capital BDC (CCAP) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Crescent Capital BDC (CCAP) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Crescent Capital BDC (CCAP) Increases Despite Market Slip: Here's What You Need to Know
by Zacks Equity Research
In the closing of the recent trading day, Crescent Capital BDC (CCAP) stood at $16.27, denoting a +0.93% change from the preceding trading day.
Crescent Capital BDC (CCAP) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
The latest trading day saw Crescent Capital BDC (CCAP) settling at $16.12, representing a -0.31% change from its previous close.
Crescent Capital BDC (CCAP) Dips More Than Broader Market: What You Should Know
by Zacks Equity Research
Crescent Capital BDC (CCAP) reachead $16.38 at the closing of the latest trading day, reflecting a -1.62% change compared to its last close.
Crescent Capital BDC (CCAP) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the most recent trading session, Crescent Capital BDC (CCAP) closed at $16.65, indicating a +1.46% shift from the previous trading day.
Crescent Capital BDC (CCAP) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
In the closing of the recent trading day, Crescent Capital BDC (CCAP) stood at $16.54, denoting a -0.72% change from the preceding trading day.
Crescent Capital BDC (CCAP) Outperforms Broader Market: What You Need to Know
by Zacks Equity Research
Crescent Capital BDC (CCAP) closed at $16.99 in the latest trading session, marking a +0.41% move from the prior day.
Crescent Capital BDC (CCAP) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Crescent Capital BDC (CCAP) closed the most recent trading day at $17.20, moving -0.23% from the previous trading session.
Crescent Capital BDC (CCAP) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
In the latest trading session, Crescent Capital BDC (CCAP) closed at $15.55, marking a -0.51% move from the previous day.
Crescent Capital BDC (CCAP) Registers a Bigger Fall Than the Market: Important Facts to Note
by Zacks Equity Research
In the latest trading session, Crescent Capital BDC (CCAP) closed at $15.58, marking a -1.45% move from the previous day.